Synonyms: pozelimab-bbfg | REGN-3918 | REGN3918 | Veopoz®
pozelimab is an approved drug (FDA (2023))
Compound class:
Antibody
Comment: Pozelimab (REGN-3918) targets the terminal complement component C5 [1]. It is designed to inhibit complement pathway activation and complement-mediated inflammatory tissue damage.
|
Selectivity at ligand targets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
|